Cetuximab Rechallenge Study
NCT01832467
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
17
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
cetuximab-containing chemotherapy
Sponsor
Chinese University of Hong Kong